Updated Jul 16, 2026
Lowenthal Richard E is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $9.16M.
Richard E. Lowenthal is the President and CEO of ARS Pharmaceuticals, Inc., a biopharmaceutical company focused on developing innovative treatments for allergic reactions. He has been involved in multiple SEC filings related to the company's operations.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-08-21 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale | 50.0K | $14.49 | $724K |
| 2024-12-19 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $11.67 | $584K |
| 2024-12-19 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $11.67 | $584K |
| 2024-12-11 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $13.16 | $658K |
| 2024-12-11 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $13.17 | $658K |
| 2024-12-09 | SPRY | ARS Pharmaceuticals, Inc. | M — Option exercise | 11.9K | $8.42 | $100K |
| 2024-12-09 | SPRY | ARS Pharmaceuticals, Inc. | M — Option exercise | 13.8K | $1.44 | $20K |
| 2024-12-09 | SPRY | ARS Pharmaceuticals, Inc. | M — Option exercise | 11.9K | $8.42 | $100K |
| 2024-11-21 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $13.95 | $697K |
| 2024-11-21 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $13.95 | $698K |
| 2024-11-14 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 4.9K | $17.64 | $86K |
| 2024-11-14 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 45.1K | $16.76 | $756K |
| 2024-11-14 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 5.0K | $17.64 | $87K |
| 2024-11-14 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 45.0K | $16.76 | $755K |
| 2024-10-17 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $14.88 | $744K |
| 2024-10-17 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 1.4K | $15.25 | $22K |
| 2024-10-17 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 48.5K | $14.86 | $722K |
| 2024-10-10 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $13.83 | $691K |
| 2024-10-10 | SPRY | ARS Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 50.0K | $13.83 | $691K |
Richard E. Lowenthal is the President and CEO of ARS Pharmaceuticals, Inc., a biopharmaceutical company focused on developing innovative treatments for allergic reactions. He has been involved in multiple SEC filings related to the company's operations.…
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($9.16M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lowenthal Richard E profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.